The core of the argument is deceptively simple. A platelet count tells you how many platelets are circulating, but says nothing about whether they work. Platelets contribute to hemostasis through adhesion, activation, granule release, aggregation, and support of thrombin generation, and none of these functions is captured by a routine count. Multiple studies have now documented profound platelet dysfunction in patients with traumatic brain injury even when their counts sit comfortably within the normal range. The authors define this dysfunction as a measurable impairment in agonist-induced aggregation, in the responsiveness of specific receptor pathways, or in the platelet’s contribution to whole-blood clot strength, occurring disproportionately to or entirely in the absence of thrombocytopenia. In other words, a patient can have plenty of platelets and still have platelets that fail.

The biological explanation lies in the unique nature of brain injury. When neural tissue is disrupted, it releases tissue factor, damage-associated molecular patterns, microparticles, and lipid mediators into the circulation, triggering thrombin generation, platelet activation, and ultimately receptor desensitization. The result is a paradoxical hemostatic state the authors describe as activation exhaustion: early procoagulant activation coexists with downstream hyporesponsiveness. Platelet activation and platelet dysfunction, far from being mutually exclusive, appear to be overlapping temporal phases of the same post-injury response. This may explain a frustrating clinical pattern in which patients with traumatic brain injury suffer early hemorrhagic progression of their intracranial lesions and later develop thrombotic complications, two seemingly opposite outcomes arising from the same underlying biology.

The strongest mechanistic evidence comes from a study by Castellino and colleagues, who examined 70 patients with isolated head injury, carefully excluding hemorrhagic shock, hypotension, and antiplatelet medication use. In severe traumatic brain injury, they found adenosine diphosphate, or ADP, pathway inhibition of 93.1 percent, with an interquartile range of 44.8 to 98.3 percent, compared with just 15.5 percent in controls, a difference that was highly statistically significant, and the arachidonic acid pathway was involved concurrently. A parallel rat model confirmed ADP inhibition of 77.6 percent, plus or minus 6.7 percent, just 15 minutes after injury. These findings establish that brain injury alone, independent of systemic hemodynamic compromise, generates profound receptor-level platelet dysfunction, a mechanism distinct from pharmacological blockade and from inhibition driven by circulating mediators.

Current clinical guidelines recommend maintaining platelet counts above 50 billion per liter in active intracranial hemorrhage and above 100 billion per liter around surgery. Those thresholds remain essential, the authors stress, but they address only quantity. A patient whose count is well above both limits may still harbor significant dysfunction at the level of the ADP/P2Y12 or arachidonic acid/cyclooxygenase-1 receptor pathways. The authors also warn against two opposite errors: equating thrombocytopenia with platelet failure, and treating any detected dysfunction as an automatic indication for transfusion. Their framework rests on three clinical questions: which phenotype is present, is it clinically meaningful, and can correcting it actually improve outcomes?

Detecting these phenotypes requires functional testing, and here the landscape is complicated. Standard coagulation tests, including prothrombin time, international normalized ratio, and fibrinogen measurement, are essentially blind to platelet function. Viscoelastic assays such as thromboelastography and rotational thromboelastometry assess whole-blood clot kinetics and strength, and platelet mapping modules add agonist-specific response data. Other platforms, including Multiplate, VerifyNow, and light transmission aggregometry, measure different biological parameters and cannot be directly compared with one another. Cross-platform equivalence in traumatic brain injury has not been established, and the most frequently cited working thresholds, ADP or arachidonic acid inhibition greater than 60 percent on thromboelastography with platelet mapping, were never prospectively validated. They represent observational approximations, not clinical standards, and no universally accepted intervention cutoffs exist for any platform.

The therapeutic evidence is strikingly discordant, and the authors argue that the discordance follows a pattern rather than being random. On the positive side, one retrospective series found that goal-directed platelet transfusion guided by platelet mapping in severe traumatic brain injury was associated with lower mortality, and a platelet mapping algorithm reduced transfusion exposure without apparent harm in patients exposed to antiplatelet drugs. Against this, multiple studies found no benefit and potential harm from empirical platelet transfusion or desmopressin in less severely injured populations or when treatment was not guided by functional testing. The positive studies were conducted in severe injury with documented profound dysfunction and function-guided decisions; the negative studies applied empirical treatment in milder populations. The lesson, the authors conclude, is that intervention should be phenotype-guided and risk-stratified, not routine and empirical.

The risks of getting this wrong are not trivial. Platelet transfusion carries the danger of transfusion-associated circulatory overload, transfusion-related acute lung injury, alloimmunization, and prothrombotic complications, while desmopressin, typically dosed at 0.3 to 0.4 micrograms per kilogram intravenously in structured protocols, can cause hyponatremia, fluid retention, and thrombosis. The authors frame their recommendation through the lens of patient blood management: the question is not whether platelets are good or bad, but whether a clinically relevant, modifiable phenotype exists in which intervention is likely to change meaningful outcomes. They propose a five-category taxonomy matching platelet-related phenotypes to clinical context, dominant mechanism, and therapeutic implication, while candidly noting that this construct is expert-synthesized and has not been prospectively validated as a diagnostic classification system.

The practical approach they sketch is deliberately cautious. Platelet function testing is most defensible in moderate-to-severe injury, traumatic intracranial hemorrhage, radiological progression, planned neurosurgery or invasive neuromonitoring, known preinjury antiplatelet exposure, systemic polytrauma with coagulopathy, or unexplained bleeding despite a normal count. When function is preserved, empirical reversal should generally be avoided. When dysfunction is documented in high-risk patients requiring surgery or invasive monitoring, desmopressin or platelet transfusion may be considered according to phenotype, antiplatelet exposure, count, and procedural urgency, with post-intervention reassessment by clinical status, imaging, and repeat functional testing. Centers without access to viscoelastic platforms can fall back on clinical risk stratification using the Glasgow Coma Scale, lesion subtype, antiplatelet exposure, and procedural urgency, consistent with American College of Surgeons guidance. In emergent surgical scenarios, urgency simply overrides testing; in nonemergent settings, a 30-to-60-minute window permits targeted hemostatic preparation.

The authors are explicit about the limits of their case. Most clinical evidence is observational, retrospective, or single-center; interassay discordance remains a fundamental barrier; dysfunction rarely occurs in isolation and overlaps with fibrinogen abnormalities, acidosis, hypothermia, hypocalcemia, and hemodilution; the dynamic evolution of dysfunction over the first 72 hours is poorly characterized; and findings from moderate-to-severe cohorts cannot be extrapolated to mild injury. Many studies report laboratory correction without demonstrating improved patient outcomes. What they call for is a new generation of prospective, multicenter trials to determine which assay best identifies clinically meaningful dysfunction, which threshold predicts hemorrhagic progression, and whether phenotype-guided correction improves neurological outcomes rather than merely normalizing laboratory values. In neurocritical care, they write, what is hidden beyond the platelet count may be clinically decisive, and the next step is not simply to transfuse more platelets but to understand which platelet phenotype matters, when it matters, and how it can be safely corrected.

Subject of Research: Platelet dysfunction as a hemostatic phenotype in traumatic brain injury coagulopathy

Article Title: Rethinking Platelet Dysfunction in Traumatic Brain Injury: From Platelet Count to Hemostatic Phenotype

Article References: Quintana Diaz, M., & Godoy, D. A. (2026). Rethinking Platelet Dysfunction in Traumatic Brain Injury: From Platelet Count to Hemostatic Phenotype. Neurocritical Care. https://doi.org/10.1007/s12028-026-02670-5

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02670-5

Keywords: traumatic brain injury, platelet dysfunction, coagulopathy, hemostatic phenotype, thromboelastography, platelet mapping, platelet transfusion, desmopressin, intracranial hemorrhage, neurocritical care, patient blood management, P2Y12 pathway

The letter, authored by Barina Khan of Karachi Medical and Dental College and published on 3 September 2026 as Volume 29, article number 59 of the journal, is written in direct response to a pilot study by Tran and colleagues that documented dynamic platelet dysfunction in patients undergoing extracorporeal membrane oxygenation. That pilot work, which appeared in the same journal earlier in 2026, used platelet function testing to follow how platelet performance changed over the course of ECMO support and explored whether those changes tracked with clinically significant bleeding. The new letter does not dispute that platelet dysfunction is real and important in ECMO patients. Instead, it questions whether the specific instrument and protocol used can reliably detect it in this population.

The core of the concern lies in what laboratory scientists call a ceiling effect. The PFA-200 measures the time it takes for platelets, under controlled high shear conditions, to form a plug that occludes a microscopic aperture in a cartridge coated with platelet agonists such as collagen and epinephrine or collagen and adenosine diphosphate. When platelet function is severely impaired, the plug simply never forms, and the instrument reports a result at or above the maximum assay limit, typically a value greater than 300 seconds. In profoundly thrombocytopenic or platelet-exhausted patients, which many ECMO patients quickly become, large numbers of test results pile up at this artificial ceiling. Once a value has been censored at the upper limit, the assay can no longer distinguish between moderately severe and catastrophic platelet failure, compressing exactly the range of dysfunction that matters most for predicting bleeding.

Khan’s letter argues that this censoring problem is particularly acute during ECMO, where platelet counts fall progressively, platelets become activated and exhausted through continuous contact with the oxygenator membrane and circuit tubing, and acquired platelet defects accumulate over days of support. If a study correlates closure times with bleeding episodes in such a cohort, the relationship may be flattened or distorted by the many results that read simply as greater than 300 seconds. Statistical associations computed on censored data risk either underestimating the true strength of the link between platelet failure and hemorrhage or, depending on how the ceiling values are handled in the analysis, producing misleading conclusions about when platelet dysfunction begins to matter clinically.

The second confounder the letter highlights is hematocrit, the proportion of blood volume occupied by red blood cells. It is a long-standing observation in hematology that the PFA-100 and PFA-200 are exquisitely sensitive to the hematocrit of the sample. Red cells are not passive bystanders in primary hemostasis; they physically push platelets toward the vessel wall in flowing blood and contribute chemical signals, including adenosine diphosphate released from erythrocytes, that amplify platelet activation. When the hematocrit drops below roughly 30 percent, closure times lengthen even if platelets themselves are functioning normally, and severe anemia can push closure times beyond the assay limit on its own. Conversely, elevating the hematocrit can shorten closure times and mask genuine platelet defects, an effect documented decades ago in studies of uremic and cirrhotic patients evaluated on the platelet function analyzer.

This sensitivity is a serious problem in the ECMO population specifically. Patients on extracorporeal support are frequently anemic, whether from hemodilution caused by circuit priming, hemolysis within the circuit, repeated blood sampling, gastrointestinal bleeding, or the suppressed red cell production that accompanies critical illness. In such patients, a prolonged closure time may reflect the red cell deficit rather than intrinsic platelet failure, and the degree of prolongation may bear little relationship to the true functional capacity of the platelets. Khan’s letter suggests that unless hematocrit is either matched across study groups or formally adjusted for in the statistical model, the association reported between PFA-200 closure times and bleeding in ECMO patients may be confounded from the outset, with anemia masquerading as platelet dysfunction.

The letter places these concerns in a broader and somewhat sobering context. The clinical utility of closure times on the platelet function analyzer has been debated for more than two decades. Studies in cardiac surgery patients have repeatedly questioned whether the device predicts blood loss after cardiopulmonary bypass, another setting in which acquired platelet defects, hemodilution and anemia coexist. A comprehensive review in the American Journal of Hematology catalogued the assay’s utility across bleeding disorders while also documenting its susceptibility to hematologic variables, and a worldwide survey of platelet function testing practices conducted under the auspices of the International Society on Thrombosis and Haemostasis underscored how much variability exists in how platelet function is assessed even among expert laboratories. Against that backdrop, applying the PFA-200 to the uniquely harsh environment of extracorporeal circulation demands particular caution about the assay’s known limitations.

None of this means the assay should be abandoned in the ECMO setting, the letter’s argument implies, but rather that its results must be interpreted with an awareness of when the instrument can and cannot see. Practical strategies exist. Researchers can report the proportion of censored results explicitly and use statistical methods designed for data with detection limits rather than treating the ceiling value as a genuine number. Studies can stratify closure times by hematocrit, exclude samples with severe anemia from platelet-focused analyses, or measure closure times only after red cell transfusion has stabilized the hematocrit. Complementary tests that are less dependent on shear, hematocrit and sample handling, such as light transmission aggregometry, flow cytometric markers of platelet activation, or other point-of-care viscoelastic and platelet-mapping devices, can help triangulate the true state of platelet function. The pilot study’s central observation, that platelet dysfunction evolves dynamically during ECMO, remains valuable; the question is whether the PFA-200, as deployed, is measuring that dysfunction or partly measuring the anemia around it.

The stakes are far from academic. Bleeding remains one of the most feared complications of ECMO, occurring in a substantial fraction of patients and driving decisions about anticoagulation intensity, transfusion thresholds and circuit management. If closure times on the PFA-200 are adopted as a bedside guide without accounting for ceiling effects and hematocrit, clinicians risk both false reassurance, when an apparently normal result is actually capped by the assay limit in a patient with profound platelet exhaustion, and false alarm, when a prolonged result in an anemic patient triggers unnecessary platelet transfusion. Given that platelet transfusions carry their own risks, including allergic reactions, transfusion-associated circulatory overload and the theoretical promotion of thrombosis in a patient group already prone to circuit clotting, refining which patients truly need platelet support is a matter of real clinical consequence.

Khan’s letter is a compact methodological intervention, but it lands at a moment when interest in platelet function testing during extracorporeal support is growing rapidly. As devices for measuring closure times, aggregometry and platelet activation migrate from hematology laboratories to the intensive care unit bedside, the letter serves as a reminder that the validity of any such measurement depends on the biology of the sample as much as the precision of the instrument. In ECMO patients, where thrombocytopenia, platelet exhaustion and anemia march together, closure times must be read with both eyes open. Whether future studies can confirm a robust, hematocrit-independent association between PFA-200 results and bleeding in this population will determine whether the assay earns a genuine place in the ECMO management toolkit, or remains a test whose ceiling it cannot see above and whose red cell context it cannot escape.

Subject of Research: The reliability of PFA-200 platelet function closure times for assessing bleeding risk during extracorporeal membrane oxygenation

Article Title: PFA-200 closure times in ECMO: Are ceiling effects and hematocrit confounding the bleeding association?

Article References: Khan, B. (2026). PFA-200 closure times in ECMO: Are ceiling effects and hematocrit confounding the bleeding association?. Journal of Artificial Organs, 29(4), Article 59. https://doi.org/10.1007/s10047-026-01589-0

Image Credits: AI Generated

DOI: 10.1007/s10047-026-01589-0

Keywords: ECMO, PFA-200, platelet function, closure time, bleeding risk, hematocrit, coagulation, extracorporeal membrane oxygenation, platelet dysfunction, anemia, point-of-care testing, Journal of Artificial Organs